RU2131251C1 - Производные роданина, способ их получения, фармацевтическая композиция, использование в качестве гипогликемических агентов и для лечения болезни альцгеймера - Google Patents

Производные роданина, способ их получения, фармацевтическая композиция, использование в качестве гипогликемических агентов и для лечения болезни альцгеймера Download PDF

Info

Publication number
RU2131251C1
RU2131251C1 RU93051176A RU93051176A RU2131251C1 RU 2131251 C1 RU2131251 C1 RU 2131251C1 RU 93051176 A RU93051176 A RU 93051176A RU 93051176 A RU93051176 A RU 93051176A RU 2131251 C1 RU2131251 C1 RU 2131251C1
Authority
RU
Russia
Prior art keywords
alkyl
hydrogen
phenyl
thioxo
thiazolidinone
Prior art date
Application number
RU93051176A
Other languages
English (en)
Russian (ru)
Other versions
RU93051176A (ru
Inventor
Мауд Бью-Валлескей Джулиана
Чарльз Ханден Дэвид
Дэвид Джонс Чарльз
Энн Панетта Джилл
Норман Шоу Уолтер
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of RU93051176A publication Critical patent/RU93051176A/ru
Application granted granted Critical
Publication of RU2131251C1 publication Critical patent/RU2131251C1/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65H—HANDLING THIN OR FILAMENTARY MATERIAL, e.g. SHEETS, WEBS, CABLES
    • B65H2511/00—Dimensions; Position; Numbers; Identification; Occurrences
    • B65H2511/50—Occurence
    • B65H2511/51—Presence
    • B65H2511/512—Marks, e.g. invisible to the human eye; Patterns

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU93051176A 1992-09-10 1993-09-08 Производные роданина, способ их получения, фармацевтическая композиция, использование в качестве гипогликемических агентов и для лечения болезни альцгеймера RU2131251C1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94335392A 1992-09-10 1992-09-10
US07/943,353 1992-09-10

Publications (2)

Publication Number Publication Date
RU93051176A RU93051176A (ru) 1996-11-10
RU2131251C1 true RU2131251C1 (ru) 1999-06-10

Family

ID=25479507

Family Applications (1)

Application Number Title Priority Date Filing Date
RU93051176A RU2131251C1 (ru) 1992-09-10 1993-09-08 Производные роданина, способ их получения, фармацевтическая композиция, использование в качестве гипогликемических агентов и для лечения болезни альцгеймера

Country Status (20)

Country Link
US (3) US5523314A (https=)
EP (2) EP0587377A3 (https=)
JP (1) JPH06192091A (https=)
KR (1) KR940006590A (https=)
CN (1) CN1091006A (https=)
AU (1) AU676843B2 (https=)
CA (1) CA2105598A1 (https=)
CZ (1) CZ181493A3 (https=)
FI (1) FI933946A7 (https=)
HU (1) HUT70184A (https=)
IL (1) IL106877A (https=)
MX (1) MX9305444A (https=)
MY (1) MY131443A (https=)
NO (2) NO933198L (https=)
NZ (1) NZ248573A (https=)
PL (1) PL300335A1 (https=)
RU (1) RU2131251C1 (https=)
TW (1) TW274546B (https=)
YU (1) YU59593A (https=)
ZA (1) ZA936492B (https=)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005119252A2 (en) * 2004-05-26 2005-12-15 Arena Pharmaceuticals, Inc. Modulators of gpr35 for the treatment of metabolic-related disorders
NZ248573A (en) * 1992-09-10 1996-02-27 Lilly Co Eli 5-arylmethyl (and methylidene) thiazolidin-4-one derivatives; their preparation and pharmaceutical compositions
GB9321221D0 (en) * 1993-10-14 1993-12-01 Glaxo Spa Heterocyclic compounds
US6251928B1 (en) * 1994-03-16 2001-06-26 Eli Lilly And Company Treatment of alzheimer's disease employing inhibitors of cathepsin D
ATE238297T1 (de) * 1994-10-20 2003-05-15 Nippon Chemiphar Co Chinolinderivat
US5563277A (en) * 1994-12-21 1996-10-08 Eli Lilly And Company Process for preparing benzyl-substituted rhodanine derivatives
IL117208A0 (en) * 1995-02-23 1996-06-18 Nissan Chemical Ind Ltd Indole type thiazolidines
CA2221684A1 (en) * 1995-06-06 1996-12-12 Athena Neurosciences, Inc. Novel cathepsin and methods and compositions for inhibition thereof
US5849711A (en) * 1995-06-06 1998-12-15 Athena Neurosciences, Inc. Cathepsin and methods and compositions for inhibition thereof
US5783434A (en) * 1995-06-06 1998-07-21 Tung; Jay S. Cathepsin and methods and compositions for inhibition thereof
JPH09176162A (ja) * 1995-12-22 1997-07-08 Toubishi Yakuhin Kogyo Kk チアゾリジンジオン誘導体及びその製造法並びにそれを含む医薬組成物
AU726664B2 (en) * 1996-07-11 2000-11-16 Warner-Lambert Company Method for treating and preventing neurodegenerative disorders by administering a thiazolidinone
US6005142A (en) * 1996-09-03 1999-12-21 Eli Lilly And Company Process for preparing benzyl-substituted rhodanine derivatives
US6063799A (en) * 1996-09-03 2000-05-16 Eli Lilly And Company Alternate crystal form of Tazofelone
DE19641180A1 (de) * 1996-09-24 1998-03-26 Schering Ag Verfahren zur Darstellung von APP-Sekretase Modulation und deren Verwendung als Mittel zur Behandlung der Alzheimer'schen Erkrankung
EP1006794B1 (en) * 1997-03-12 2007-11-28 Robert W. Esmond A method for treating or preventing alzheimer's disease
EP1014974B1 (en) 1997-05-29 2004-08-11 H. Lundbeck A/S Treatment of schizophrenia and psychosis
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
AU758155B2 (en) 1998-04-29 2003-03-13 Oklahoma Medical Research Foundation Construction of retroviral producer cells from adenoviral and retroviral vectors
US6933272B1 (en) 1998-09-22 2005-08-23 Erik Helmerhorst Use of non-peptidyl compounds for the treatment of insulin related ailments
US6673816B1 (en) 1998-09-30 2004-01-06 Angelika Esswein Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders
WO2000018748A1 (en) * 1998-09-30 2000-04-06 Roche Diagnostics Gmbh Rhodanine derivatives for the treatment and prevention of metabolic bone disorders
WO2000024392A1 (en) * 1998-10-26 2000-05-04 Sumitomo Pharmaceuticals Company, Limited β-AMYLOID FORMATION INHIBITORS
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
US6127394A (en) * 1999-03-08 2000-10-03 The University Of Mississippi 1,2-Dithiolane derivatives
US6204288B1 (en) 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
MXPA01010490A (es) * 1999-06-10 2005-05-27 Warner Lambert Co Derivados rodanina para usarse en un metodo de inhibicion de la agregacion de proteinas amiloides y la formacion de imagenes de los depositos amiloides.
TR200103561T2 (tr) * 1999-06-10 2002-04-22 Warner Lambert Company Rodanin türevleri ve amiloidlerin önlenmesi ve görüntülenmesinde kullanımları
WO2001002394A1 (en) * 1999-07-01 2001-01-11 Geron Corporation Substituted indole compounds and their use for the treatment of cancer
EP1593677A3 (en) * 1999-08-31 2006-01-04 Incyte San Diego Incorporated Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes
JP2003508391A (ja) * 1999-08-31 2003-03-04 マキシア・ファーマシューティカルズ・インコーポレイテッド ベンジリデン−チアゾリジンジオン類およびアナログ類ならびに糖尿病の治療におけるその使用
US20070060606A1 (en) * 1999-10-07 2007-03-15 Robertson Harold A Compounds and methods for modulating phosphodiesterase 10A
US6706766B2 (en) * 1999-12-13 2004-03-16 President And Fellows Of Harvard College Small molecules used to increase cell death
US6620830B2 (en) 2000-04-21 2003-09-16 Pfizer, Inc. Thyroid receptor ligands
EP1148054B1 (en) * 2000-04-21 2005-11-23 Pfizer Products Inc. Thyroid receptor ligands
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
DE60113407T2 (de) * 2000-05-04 2006-06-29 Warner-Lambert Co. Llc Verfahren zur hemmung von amyloidprotein aggregation und zur diagnostischen nachweis von amyloidablagerung unter verwendung von aminoindanderivaten
GB0021421D0 (en) * 2000-08-31 2000-10-18 Oxford Glycosciences Uk Ltd Compounds
AU2002252227A1 (en) 2001-03-07 2002-09-24 Maxia Pharmaceuticals, Inc. Heterocyclic derivatives for the treatment of cancer and other proliferative diseases
JP2004523571A (ja) * 2001-03-08 2004-08-05 マキシア・ファーマシューティカルズ・インコーポレイテッド Ｒｘｒ活性化分子
CA2340824A1 (en) * 2001-03-14 2002-09-14 Ibm Canada Limited-Ibm Canada Limitee Method and system for application behavior analysis
WO2003016267A1 (en) * 2001-08-17 2003-02-27 Incyte San Diego Incorporated Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia
JP2005513026A (ja) * 2001-11-15 2005-05-12 インサイト サン ディエゴ インコーポレイテッド 高コレステロール血症、異脂肪血症および他の代謝障害；癌、および他の疾患を治療するｎ−置換複素環
US7102000B2 (en) * 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
US7196108B2 (en) * 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
JP4782564B2 (ja) * 2002-07-10 2011-09-28 メルク セローノ ソシエテ アノニム アゾリジノン−ビニル縮合−ベンゼン誘導体
US7005523B2 (en) * 2002-08-30 2006-02-28 Pfizer Inc. Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines
AU2003291024A1 (en) * 2002-11-13 2004-06-03 Rigel Pharmaceuticals, Inc. Rhodanine derivatives and pharmaceutical compositions containing them
CN100579978C (zh) 2002-11-22 2010-01-13 史密丝克莱恩比彻姆公司 化合物
US20050014767A1 (en) * 2003-01-29 2005-01-20 Magnus Pfahl Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases
CA2518465A1 (en) 2003-03-25 2004-10-14 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US20050038098A1 (en) * 2003-04-18 2005-02-17 Catherine Tachdjian Substituted dihydronaphthalene and isochroman compounds for the treatment of metabolic disorders, cancer and other diseases
US20060106077A1 (en) * 2003-07-18 2006-05-18 Pintex Pharmaceuticals, Inc. Pin1-Modulating compounds and methods of use thereof
KR20060041309A (ko) 2003-08-13 2006-05-11 다케다 야쿠힌 고교 가부시키가이샤 ４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
EP1699777B1 (en) 2003-09-08 2012-12-12 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
UA85871C2 (uk) 2004-03-15 2009-03-10 Такеда Фармасьютікал Компані Лімітед Інгібітори дипептидилпептидази
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
JP2008524331A (ja) 2004-12-21 2008-07-10 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤
DE102005022182A1 (de) * 2005-05-09 2006-11-16 Combinature Biopharm Ag Modulatoren der PDZ-Domäne
PE20070083A1 (es) * 2005-06-08 2007-01-27 Smithkline Beecham Corp (5z)-5-(6-quinoxalinilmetilideno)-2-[(2,6-diclorofenil)amino]-1,3-tiazol-4(5h)-ona
MY147393A (en) 2005-09-14 2012-11-30 Takeda Pharmaceutical Administration of dipeptidyl peptidase inhibitors
CA2622642C (en) 2005-09-16 2013-12-31 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
KR100814109B1 (ko) * 2006-01-09 2008-03-14 한국생명공학연구원 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 약학적 조성물
JP5315060B2 (ja) 2006-02-03 2013-10-16 バイオノミックス リミテッド 置換ベンゾフラン、ベンゾチオフェン、ベンゾセレノフェンおよびインドールおよびそれらのチューブリン重合阻害剤としての使用
DE112007001030T5 (de) 2006-04-28 2009-02-26 Kagoshima University Amyloid-ß-Fibrillogenese-inhibierendes Peptid
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US20100286041A1 (en) * 2007-03-22 2010-11-11 Smithkline Beecham Corporation (5z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5h)-one
KR101335021B1 (ko) 2007-07-31 2013-12-12 액세라인크 게놈 테스트의 용도 및 인지 기능 저하 치료용 케톤성 화합물
US8466177B2 (en) * 2007-11-01 2013-06-18 The Uab Research Foundation Treating and preventing viral infections
CA2735578C (en) * 2008-08-12 2018-10-23 Zinfandel Pharmaceuticals, Inc. Method of identifying risk factors for alzheimer's disease comprising tomm40 gene variants
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
AU2010232923A1 (en) * 2009-04-03 2011-11-03 Medisyn Technologies, Inc. Compositions for treatment of Alzheimer's disease
PL2516425T3 (pl) * 2009-12-23 2016-03-31 Jasco Pharmaceuticals Llc Inhibitory kinaz aminopirydynowych
JP5733716B2 (ja) * 2009-12-25 2015-06-10 キヤノン株式会社 中枢神経系組織標識用組成物、中枢神経系組織の標識方法、及び中枢神経系組織標識用組成物を用いたスクリーニング方法
CN102558088A (zh) * 2010-12-31 2012-07-11 中国科学院上海药物研究所 联苯亚甲基-2-硫代-4-噻唑酮类化合物及其制备方法和用途
EA201391017A1 (ru) 2011-01-10 2014-04-30 Зинфандел Фармасьютикалз, Инк. Способы и готовые лекарственные формы для лечения болезни альцгеймера
US9056862B2 (en) 2011-05-10 2015-06-16 National University Corporation Kobe University Thioxothiazolidine derivative having Ras function inhibitory effect
US20150133467A1 (en) * 2012-06-06 2015-05-14 Kyoto University Screening method, protein instability and/or stability inducers, and protein activity assessment
EP2914250B1 (en) 2012-11-05 2018-04-04 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Combination of an anti-cancer agent such as a tyrosinekinase inhibitor and a stat5 antagonist, preferably a thiazolidinedione, for eliminating hematologic cancer stem cells in vivo and for preventing hematologic cancer relapse
WO2016077793A1 (en) * 2014-11-14 2016-05-19 Children's Hospital Medical Center Sos1 inhibitors for cancer treatment
CN104557767B (zh) * 2015-01-14 2016-06-29 成都中医药大学 罗丹宁手性环己烷螺环化合物及其制备方法与用途
CN106008494B (zh) * 2016-05-31 2019-08-27 广东工业大学 一种含4-氧代-2-硫代噻唑烷基衍生物及其制备方法与应用
EP4083037A4 (en) * 2019-12-26 2024-01-24 Yonsei University, University-Industry Foundation(UIF). Pyrrolidine derivative, and pharmaceutical composition for preventing or treating beta-amyloid or tau protein-associated diseases containing same

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU173773A (https=) *
EP0045165A1 (en) * 1980-07-28 1982-02-03 Ono Pharmaceutical Co., Ltd. Rhodanine derivatives, a process for their preparation, and aldose reductase inhibitors containing such derivatives
EP0047109A1 (en) * 1980-08-22 1982-03-10 Ono Pharmaceutical Co., Ltd. Rhodanine derivatives, process for their preparation, and aldose reductase inhibitor containing the rhodanine derivatives as active ingredient
EP0208040A2 (en) * 1985-07-10 1987-01-14 Taiho Pharmaceutical Company Limited Rhodanine derivatives and a process for preparing same
EP0316723A1 (en) * 1987-11-20 1989-05-24 Hoechst-Roussel Pharmaceuticals Incorporated 3-[4(1-Substituted-4-piperazinyl)butyl]-4-thiazolidinones a process for their preparation and their use as medicaments
EP0391644A2 (en) * 1989-04-07 1990-10-10 Eli Lilly And Company Aryl-substituted rhodanine derivatives
EP0398179A1 (en) * 1989-05-19 1990-11-22 Nisshin Flour Milling Co., Ltd. Rhodanine derivatives and pharmaceutical compositions
DE4027038A1 (de) * 1990-08-27 1992-03-05 Wella Ag 3-amino-5-benzyliden-2-thioxo-thiazolidin-4- one, verfahren zu deren herstellung und diese enthaltendes kosmetisches mittel
EP0499216A1 (en) * 1991-02-15 1992-08-19 MITSUI TOATSU CHEMICALS, Inc. Transparent impact-resistant molded articles
EP0500337A1 (en) * 1991-02-22 1992-08-26 University Of Colorado Foundation, Inc. Composition containing aryl-substituted rhodanine derivatives for the treatment of type I diabetes
US5143929A (en) * 1991-05-09 1992-09-01 Warner-Lambert Company 2-substituted thiazolidinone, oxazolidinone, and imidazolidinone derivatives of fenamates as antiinflammatory agents

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1038050B (de) * 1955-11-17 1958-09-04 Farmaceutici Italia S A Soc Verfahren zur Herstellung von 5-(3', 4'-Dioxybenzyliden)-Derivaten heterocyclischer Verbindungen
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) * 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
AU6610081A (en) * 1980-01-24 1981-07-30 Senju Pharmaceutical Co., Ltd. Thiazolidine derivatives
US4636516A (en) * 1981-02-19 1987-01-13 Yamanouchi Pharmaceutical Co., Ltd. 3,5-di-tert-butyl-4-hydroxyphenyl-substituted heterocyclic compounds
JPS58118577A (ja) * 1982-01-07 1983-07-14 Takeda Chem Ind Ltd チアゾリジン誘導体
US4617312A (en) * 1983-01-17 1986-10-14 Pfizer Inc. Aldose reductase inhibiting 5-(2-alkoxyphenyl) thiazolidinediones
US4552891A (en) * 1983-09-13 1985-11-12 Eli Lilly And Company Benzothiophene derivatives
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
HU210339B (en) * 1985-05-21 1995-03-28 Pfizer Process for preparing thiazolidinediones and their pharmaceutical compositions haring hypoglycemic effect
JPH06779B2 (ja) * 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US5356917A (en) * 1985-08-09 1994-10-18 Eli Lilly And Company Aryl-substituted rhodanine derivatives
IL79648A (en) * 1985-08-09 1991-12-12 Lilly Co Eli Pharmaceutical anti-inflammatory and ischemia preventing compositions containing di-t-butylphenol derivatives,some such novel compounds and process for their preparation
CA1325222C (en) * 1985-08-23 1993-12-14 Lederle (Japan), Ltd. Process for producing 4-biphenylylacetic acid
DK4487A (da) * 1986-01-07 1987-07-08 Yamanouchi Pharma Co Ltd Heterocycliske forbindelser og farmaceutiske praeparater indeholdende disse
US4971996A (en) * 1987-03-11 1990-11-20 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Hydroxystyrene compounds which are useful as tyrosine kinase inhibitors
FI91869C (fi) * 1987-03-18 1994-08-25 Tanabe Seiyaku Co Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
US5260445A (en) * 1987-09-04 1993-11-09 Beecham Group P.L.C. 2,4-thiazolidinediones
US5223522A (en) * 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
US5330998A (en) * 1988-03-08 1994-07-19 Pfizer Inc. Thiazolidinedione derivatives as hypoglycemic agents
IE62214B1 (en) * 1988-05-25 1995-01-11 Warner Lambert Co Arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflammatory agents
US5208250A (en) * 1988-05-25 1993-05-04 Warner-Lambert Company Known and selected novel arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and anti-inflammatory agents
US4863923A (en) * 1988-07-01 1989-09-05 Eli Lilly And Company Method of inhibiting superoxide release
JPH02300119A (ja) * 1989-05-11 1990-12-12 Kanegafuchi Chem Ind Co Ltd 過酸化脂質生成抑制剤
GB8919434D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
US4997948A (en) * 1989-10-27 1991-03-05 American Home Products 5-[(1- and 2-naphthalenyl) sulfonyl]-2,4-thiazolidinediones and derivatives thereof
IL108962A (en) * 1989-12-21 1996-12-05 Lilly Co Eli Use of hydroxybenzyl substituted sulfur containing heterocyclic derivatives a process for their preparation and pharmaceutical compositions containing them
US5143928A (en) * 1990-03-27 1992-09-01 Warner-Lambert Company 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents
FR2680512B1 (fr) * 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
NO179246C (no) * 1991-11-20 1996-09-04 Sankyo Co Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav
US5320770A (en) * 1992-04-27 1994-06-14 Dow Corning Corporation Electrorheological (ER) fluid based on amino acid containing metal polyoxo-salts
AU679675B2 (en) * 1992-05-11 1997-07-10 Bayer Corporation Methods for detecting beta amyloid precursor protein processing enzymes
US5236941A (en) * 1992-06-30 1993-08-17 American Home Products Corporation 5-(2-hydroxy-1-arylethylidene)- and 5-(2-oxo-1-arylethylidene)-2,4-thiazolidinediones and derivatives thereof
NZ248573A (en) * 1992-09-10 1996-02-27 Lilly Co Eli 5-arylmethyl (and methylidene) thiazolidin-4-one derivatives; their preparation and pharmaceutical compositions
US5506745A (en) * 1994-08-05 1996-04-09 Xerox Corporation Hollow conformable charge roll

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU173773A (https=) *
EP0045165A1 (en) * 1980-07-28 1982-02-03 Ono Pharmaceutical Co., Ltd. Rhodanine derivatives, a process for their preparation, and aldose reductase inhibitors containing such derivatives
EP0047109A1 (en) * 1980-08-22 1982-03-10 Ono Pharmaceutical Co., Ltd. Rhodanine derivatives, process for their preparation, and aldose reductase inhibitor containing the rhodanine derivatives as active ingredient
EP0208040A2 (en) * 1985-07-10 1987-01-14 Taiho Pharmaceutical Company Limited Rhodanine derivatives and a process for preparing same
EP0316723A1 (en) * 1987-11-20 1989-05-24 Hoechst-Roussel Pharmaceuticals Incorporated 3-[4(1-Substituted-4-piperazinyl)butyl]-4-thiazolidinones a process for their preparation and their use as medicaments
EP0391644A2 (en) * 1989-04-07 1990-10-10 Eli Lilly And Company Aryl-substituted rhodanine derivatives
EP0398179A1 (en) * 1989-05-19 1990-11-22 Nisshin Flour Milling Co., Ltd. Rhodanine derivatives and pharmaceutical compositions
DE4027038A1 (de) * 1990-08-27 1992-03-05 Wella Ag 3-amino-5-benzyliden-2-thioxo-thiazolidin-4- one, verfahren zu deren herstellung und diese enthaltendes kosmetisches mittel
EP0499216A1 (en) * 1991-02-15 1992-08-19 MITSUI TOATSU CHEMICALS, Inc. Transparent impact-resistant molded articles
EP0500337A1 (en) * 1991-02-22 1992-08-26 University Of Colorado Foundation, Inc. Composition containing aryl-substituted rhodanine derivatives for the treatment of type I diabetes
US5143929A (en) * 1991-05-09 1992-09-01 Warner-Lambert Company 2-substituted thiazolidinone, oxazolidinone, and imidazolidinone derivatives of fenamates as antiinflammatory agents

Also Published As

Publication number Publication date
NO933198L (no) 1994-03-11
NO981911L (no) 1994-03-11
FI933946A0 (fi) 1993-09-09
US5523314A (en) 1996-06-04
YU59593A (sh) 1997-01-08
FI933946L (fi) 1994-03-11
MX9305444A (es) 1994-05-31
EP0915090A1 (en) 1999-05-12
ZA936492B (en) 1995-03-02
TW274546B (https=) 1996-04-21
NO981911D0 (no) 1998-04-28
IL106877A (en) 1998-03-10
US5716975A (en) 1998-02-10
CA2105598A1 (en) 1994-03-11
US5661168A (en) 1997-08-26
KR940006590A (ko) 1994-04-25
IL106877A0 (en) 1993-12-28
AU4621893A (en) 1994-03-17
CN1091006A (zh) 1994-08-24
AU676843B2 (en) 1997-03-27
PL300335A1 (en) 1994-03-21
CZ181493A3 (en) 1994-03-16
EP0587377A2 (en) 1994-03-16
FI933946A7 (fi) 1994-03-11
HUT70184A (en) 1995-09-28
EP0587377A3 (en) 1994-09-21
HU9302551D0 (en) 1993-11-29
JPH06192091A (ja) 1994-07-12
NO933198D0 (no) 1993-09-08
NZ248573A (en) 1996-02-27
MY131443A (en) 2007-08-30

Similar Documents

Publication Publication Date Title
RU2131251C1 (ru) Производные роданина, способ их получения, фармацевтическая композиция, использование в качестве гипогликемических агентов и для лечения болезни альцгеймера
KR100630258B1 (ko) 디펩티딜 펩티다제 ｉｖ의 효과인자를 포함하는 약제학적조성물
EP2120580B1 (en) Compositions and methods for the treatment of metabolic disorders
EP1628666B1 (en) Compouds and uses thereof in modulating amyloid beta
EP0677517A1 (en) Treatment of Alzheimer's disease employing inhibitors of cathepsin D
US9403815B2 (en) Compounds and uses thereof in modulating levels of various amyloid beta peptide alloforms
US7105554B2 (en) Benzylidene thiazolidinediones and their use as antimycotic agents
JP2012514032A (ja) ベンゾアリールウレイド化合物、及びこれを含有する神経退行性脳疾患予防又は治療用組成物
US7056939B2 (en) 4-(4Methoxybenzyl)-n′-(5-nitro1,3-thiazol-2-yl)urea and its use in the treatment of conditions associated with glycogen-synthase kinase-3 (gsk3)
JP2005526835A (ja) 新規な２−置換−１，３−チアゾール化合物
WO2001082919A2 (en) Methods of and compounds for inhibiting calpains
KR20090033583A (ko) 글라이신 아릴 아마이드를 포함하는 신규한베타-세크리타제 저해용 화합물
HK1013987A (en) Thiazolidinone derivatives as hypoglycemic agents and for treating alzheimer's disease
IL119119A (en) Rodinin derivatives are a process for their preparation and pharmaceutical preparations containing them
AU2003262286B2 (en) Novel Effectors of Dipeptidyl Peptidase IV
AU2006202684A1 (en) Novel effectors of dipeptidyl peptidase IV
KR20090034009A (ko) 글라이신 모액을 포함하는 신규한 베타-세크리타제 저해용화합물
HK1059397A (en) Dipeptidyl peptidase iv effectors